目的 探討雷丸膠囊聯(lián)合注射用鹽酸吉西他濱治療晚期肺癌的臨床療效。方法 選取2013年8月—2015年8月在河北北方學(xué)院附屬第一醫(yī)院進(jìn)行治療的晚期肺癌患者101例為研究對(duì)象，根據(jù)用藥的差別分成對(duì)照組（50例）和治療組（51例）。對(duì)照組于第1、8天靜脈滴注注射用鹽酸吉西他濱，1 000 mg/m²加入到生理鹽水250 mL中。治療組在對(duì)照組基礎(chǔ)上口服雷丸膠囊，1粒/次，3次/d。兩組患者均以3周為1個(gè)療程，連續(xù)治療2個(gè)療程。觀察兩組的臨床療效，比較兩組的Karnofsky（KPS）評(píng)分、生活質(zhì)量調(diào)查表（SF-36）評(píng)分和生存情況。結(jié)果 治療后，對(duì)照組和治療組的臨床有效率分別為48.00%、70.59%，疾病控制率分別為74.00%、94.12%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組KPS評(píng)分、SF-36評(píng)分均顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯高于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組腫瘤進(jìn)展時(shí)間、中位生存期、1年生存率以及2年生存率的改善情況均要優(yōu)于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 雷丸膠囊聯(lián)合注射用鹽酸吉西他濱治療晚期肺癌具有較好的臨床療效，可改善患者的生存情況與生活質(zhì)量，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Leiwan Capsules combined with Gemcitabine Hydrochloride for injection in treatment of advanced lung cancer. Methods Patients (101 cases) with advanced lung cancer in the First Affiliated Hospital of Hebei North University from August 2013 to August 2015 were randomly divided into the control group (50 cases) and the treatment group (51 cases). Patients in the control group were iv administered with Gemcitabine Hydrochloride for injection at the first and eighth day, 1 000 mg/m² added into normal saline 250 mL. Patients in the treatment group were po administered with Leiwan Capsules on the basis of the control group, 1 grains/time, three times daily. Patients in two groups were treated for 2 courses, 3 weeks as 1 course. After treatment, the clinical efficacies were evaluated, and KPS scores, SF-36 scores, and survival situation in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 48.00% and 70.59%, respectively, the disease control rates in the control and treatment groups were 74.00% and 94.12%, respectively, and there was difference between two groups (P < 0.05). After treatment, the KPS scores and SF-36 scores in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the improvement of tumor progression time, median survival, 1 year survival rate, and 2 year survival rate in the treatment group was significantly better than those in the control group, and there was difference between two groups (P < 0.05). Conclusion Leiwan Capsules combined with Gemcitabine Hydrochloride for injection has clinical curative effect in treatment of advanced lung cancer, can improve survival situation and quality of life, with good safety, which has a certain clinical application value.

河北省科技計(jì)劃項(xiàng)目（162777297）